논문 목록
2건-
Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial.
[BACKGROUND] Immune checkpoint inhibitors achieve high response rates in relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL), but few treatment options are available for patients who experience failure after PD-1/PD-L1 blockade. T…
-
Blocking TRIM47-mediated HNF4 degradation suppresses hepatocellular carcinoma progression.
Previous studies have highlighted the downregulation of hepatocyte nuclear factor 4alpha (HNF4) as a critical event in the pathogenesis of HCC. However, the mechanism of its degradation in HCC remains unclear. Tripartite motif 47 (TRIM47), …